- Home
- APLS
as 02-21-2025 4:00pm EST
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
Upcoming Earnings Alert:
Get ready for potential market movements as Apellis Pharmaceuticals Inc. APLS prepares to release earnings report on 28 Feb 2025.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 3.6B | IPO Year: | 2017 |
| Target Price: | $46.71 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Buy | Number of Analysts: | 18 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.03 | EPS Growth: | N/A |
| 52 Week Low/High: | $24.34 - $71.90 | Next Earning Date: | 02-28-2025 |
| Revenue: | $715,216,000 | Revenue Growth: | 162.10% |
| Revenue Growth (this year): | 97.25% | Revenue Growth (next year): | 12.68% |
Stock Insider Trading Activity of Apellis Pharmaceuticals Inc. (APLS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| DeLong Mark Jeffrey | APLS | Chief Business & Strat Officer | Feb 11 '25 | Sell | $28.54 | 363 | $10,359.58 | 83,945 | |
| Deschatelets Pascal | APLS | Chief Scientific Officer | Jan 29 '25 | Sell | $29.52 | 826 | $24,386.49 | 1,147,716 | |
| Nicholson Nur | APLS | Chief Technical Officer | Jan 29 '25 | Sell | $29.52 | 825 | $24,356.97 | 83,664 | |
| Watson David O. | APLS | General Counsel | Jan 29 '25 | Sell | $29.52 | 695 | $20,518.90 | 144,299 | |
| Townsend Adam J. | APLS | Chief Commercial Officer | Jan 29 '25 | Sell | $29.52 | 695 | $20,518.90 | 84,050 | |
| Lewis Karen | APLS | Chief People Officer | Jan 29 '25 | Sell | $29.52 | 364 | $10,746.59 | 70,251 | |
| Francois Cedric | APLS | Chief Executive Officer | Jan 29 '25 | Sell | $29.52 | 2,824 | $83,374.65 | 415,695 | |
| Eisele Jeffrey | APLS | Chief Development Officer | Jan 29 '25 | Sell | $29.52 | 278 | $8,207.56 | 55,312 | |
| DeLong Mark Jeffrey | APLS | Chief Business & Strat Officer | Jan 29 '25 | Sell | $29.52 | 365 | $10,776.11 | 83,945 | |
| Deschatelets Pascal | APLS | Chief Scientific Officer | Jan 22 '25 | Sell | $30.43 | 3,948 | $120,119.87 | 1,147,716 |
Latest Apellis Pharmaceuticals Inc. News
APLS Breaking Stock News: Dive into APLS Ticker-Specific Updates for Smart Investing
Simply Wall St.
19 hours ago
High Growth Tech Stocks In The United States To Watch
Insider Monkey
2 days ago
Is Apellis Pharmaceuticals (APLS) One of the Most Oversold Healthcare Stocks to Buy Now?
MT Newswires
2 days ago
Apellis Pharmaceuticals, Sobi Say EMA Validated Indication Extension Application for Potential Kidney Disease Treatment
GlobeNewswire
2 days ago
Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN
Insider Monkey
3 days ago
Apellis Pharmaceuticals (APLS): Among Top Insider Stock Buys And Sells In January
GlobeNewswire
8 days ago
Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
Simply Wall St.
9 days ago
Apellis Pharmaceuticals (NASDAQ:APLS investor one-year losses grow to 58% as the stock sheds US$231m this past week
Insider Monkey
11 days ago
Why Insiders Are Selling Apellis Pharmaceuticals, Inc. (APLS) Recently
Compare APLS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "APLS Apellis Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.